Clinical Trials Logo

Resectable Carcinoma clinical trials

View clinical trials related to Resectable Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04736485 Active, not recruiting - Clinical trials for Resectable Carcinoma

Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

GASPAR
Start date: June 28, 2021
Phase: Phase 2
Study type: Interventional

Multicenter, open-label, non randomized, phase 2 trial in resectable gastric or gastroesophageal junction adenocarcinoma: Perioperative Treatment by Spartalizumab (PDR001) in Combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT)

NCT ID: NCT04554771 Active, not recruiting - Clinical trials for Esophageal Adenocarcinoma

Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy

BASALT
Start date: January 27, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to demonstrate that stroma-targeting by tocilizumab in patients with adenocarcinoma of the esophagus or gastroesophageal junction with highly activated stroma increases efficacy of chemoradiotherapy measured by pathological response according to the Mandard criteria. Patients will be grouped for ADAM12, a non-invasive blood-borne marker of stromal activation.